Despite advances in targeting ER with tamoxifen and aromatase inhibitors, outcomes for ER+ disease have not improved as rapidly as for ER− or human epidermal growth factor receptor 2 positive (HER2+) breast cancer [5]. This evidence concerns the gene ESR1 and breast carcinoma.